Vanguard reports 0 Pulmonx (Common Stock) holdings
The Vanguard Group filed an amended Schedule 13G/A reporting that it beneficially owns 0 shares of Pulmonx Corp Common Stock (CUSIP 745848101).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
The Vanguard Group filed an amended Schedule 13G/A reporting that it beneficially owns 0 shares of Pulmonx Corp Common Stock (CUSIP 745848101). The filing states this follows an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, which resulted in certain Vanguard subsidiaries reporting ownership separately. The filing lists the filer address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim on 03/27/2026.
Insights
Vanguard reports no beneficial ownership in Pulmonx after an internal reorganization.
The filing documents an internal realignment dated January 12, 2026, citing SEC Release No. 34-39538, and states Amount beneficially owned: 0 and Percent of class: 0%.
Cash-flow treatment and any holdings now reported by specific Vanguard subsidiaries are not listed in this excerpt; subsequent filings by those separate entities could show redistributed positions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why does Vanguard report zero ownership in this Schedule 13G/A?
Who signed the Schedule 13G/A for The Vanguard Group reporting Pulmonx ownership?
What address is listed for The Vanguard Group on this filing?
Does this filing show holdings by Vanguard subsidiaries after the realignment?
AI-generated analysis. How Rhea-AI works. Not financial advice.